Aclaris Therapeutics Inc has a consensus price target of $9.25, established from looking at the 27 latest analyst ratings. The last 3 analyst ratings were released from HC Wainwright & Co., BTIG, and HC Wainwright & Co. on January 22, 2024, January 11, 2024, and December 29, 2023. With an average price target of $3 between HC Wainwright & Co., BTIG, and HC Wainwright & Co., there's an implied 136.22% upside for Aclaris Therapeutics Inc from these 3 analyst ratings.
1calculated from analyst ratings published within the last 3 years
date | ticker | Buy Now | Company | Current price | Upside/Downside | Analyst Firm | Analyst & % Accurate | Price Target Change | Rating Change | Previous / Current Rating | Get Alert |
---|---|---|---|---|---|---|---|---|---|---|---|
01/22/2024 | ACRS | Buy Now | Aclaris Therapeutics | $1.27 | — | HC Wainwright & Co. | Raghuram Selvaraju | — | Downgrade | Buy → Neutral | Get Alert |
01/11/2024 | ACRS | Buy Now | Aclaris Therapeutics | $1.27 | — | BTIG | Julian Harrison | — | Downgrade | Buy → Neutral | Get Alert |
12/29/2023 | ACRS | Buy Now | Aclaris Therapeutics | $1.27 | 608.66% | HC Wainwright & Co. | Raghuram Selvaraju | → $9 | Reiterates | Buy → Buy | Get Alert |
12/18/2023 | ACRS | Buy Now | Aclaris Therapeutics | $1.27 | -21.26% | Stifel | Alex Thompson | $2 → $1 | Maintains | Hold | Get Alert |
11/14/2023 | ACRS | Buy Now | Aclaris Therapeutics | $1.27 | 608.66% | HC Wainwright & Co. | Raghuram Selvaraju | $43 → $9 | Maintains | Buy | Get Alert |
11/14/2023 | ACRS | Buy Now | Aclaris Therapeutics | $1.27 | — | Cantor Fitzgerald | Louise Chen | — | Downgrade | Overweight → Neutral | Get Alert |
11/13/2023 | ACRS | Buy Now | Aclaris Therapeutics | $1.27 | 57.48% | Stifel | Alex Thompson | $20 → $2 | Downgrade | Buy → Hold | Get Alert |
11/13/2023 | ACRS | Buy Now | Aclaris Therapeutics | $1.27 | — | William Blair | Tim Lugo | — | Downgrade | Outperform → Market Perform | Get Alert |
10/09/2023 | ACRS | Buy Now | Aclaris Therapeutics | $1.27 | 2892.13% | Cantor Fitzgerald | Louise Chen | → $38 | Reiterates | Overweight → Overweight | Get Alert |
10/04/2023 | ACRS | Buy Now | Aclaris Therapeutics | $1.27 | 3285.83% | HC Wainwright & Co. | Raghuram Selvaraju | → $43 | Reiterates | Buy → Buy | Get Alert |
10/03/2023 | ACRS | Buy Now | Aclaris Therapeutics | $1.27 | 1632.28% | Evercore ISI Group | Gavin Clark-Gartner | → $22 | Initiates | → Outperform | Get Alert |
09/19/2023 | ACRS | Buy Now | Aclaris Therapeutics | $1.27 | 2892.13% | Cantor Fitzgerald | Louise Chen | → $38 | Reiterates | Overweight → Overweight | Get Alert |
09/19/2023 | ACRS | Buy Now | Aclaris Therapeutics | $1.27 | 3285.83% | HC Wainwright & Co. | Raghuram Selvaraju | → $43 | Reiterates | Buy → Buy | Get Alert |
09/14/2023 | ACRS | Buy Now | Aclaris Therapeutics | $1.27 | 1474.8% | Stifel | Alex Thompson | $16 → $20 | Maintains | Buy | Get Alert |
08/08/2023 | ACRS | Buy Now | Aclaris Therapeutics | $1.27 | 3285.83% | HC Wainwright & Co. | Raghuram Selvaraju | → $43 | Reiterates | Buy → Buy | Get Alert |
06/14/2023 | ACRS | Buy Now | Aclaris Therapeutics | $1.27 | 3285.83% | HC Wainwright & Co. | Raghuram Selvaraju | → $43 | Reiterates | Buy → Buy | Get Alert |
03/07/2023 | ACRS | Buy Now | Aclaris Therapeutics | $1.27 | 1553.54% | Goldman Sachs | Corinne Jenkins | $25 → $21 | Maintains | Buy | Get Alert |
03/07/2023 | ACRS | Buy Now | Aclaris Therapeutics | $1.27 | 2183.46% | BTIG | Julian Harrison | $32 → $29 | Maintains | Buy | Get Alert |
03/07/2023 | ACRS | Buy Now | Aclaris Therapeutics | $1.27 | 3285.83% | HC Wainwright & Co. | Raghuram Selvaraju | $50 → $43 | Maintains | Buy | Get Alert |
The latest price target for Aclaris Therapeutics (NASDAQ: ACRS) was reported by HC Wainwright & Co. on January 22, 2024. The analyst firm set a price target for $0.00 expecting ACRS to fall to within 12 months (a possible -100.00% downside). 16 analyst firms have reported ratings in the last year.
The latest analyst rating for Aclaris Therapeutics (NASDAQ: ACRS) was provided by HC Wainwright & Co., and Aclaris Therapeutics downgraded their neutral rating.
There is no last upgrade for Aclaris Therapeutics.
The last downgrade for Aclaris Therapeutics Inc happened on January 22, 2024 when HC Wainwright & Co. changed their price target from N/A to N/A for Aclaris Therapeutics Inc.
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Aclaris Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Aclaris Therapeutics was filed on January 22, 2024 so you should expect the next rating to be made available sometime around January 22, 2025.
While ratings are subjective and will change, the latest Aclaris Therapeutics (ACRS) rating was a downgraded with a price target of $0.00 to $0.00. The current price Aclaris Therapeutics (ACRS) is trading at is $1.27, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.